F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
23 hedge funds and large institutions have $3.96M invested in F-star Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
8% less funds holding
Funds holding: 25 → 23 (-2)
9% less capital invested
Capital invested by funds: $4.35M → $3.96M (-$395K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$93.3K |
| 2 |
Renaissance Technologies
New York
|
+$66.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$8.54K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.61K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ED
Exane Derivatives
Paris,
France
|
-$120K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.7K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$23K |
| 4 |
JP Morgan Chase
New York
|
-$3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.43K |
FSTX Hedge Fund Activity: Q3 2020 in Review
23 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2020, worth a combined $3.96M — down 9.1% from $4.35M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FSTX and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $93.3K. The largest seller was Exane Derivatives, exiting entirely with an estimated $120K sold.
- 23 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2020, down from 25 in Q2 2020.
- Funds reported $3.96M of F-star Therapeutics, Inc. Common Stock stock for Q3 2020, down 9.1% quarter-over-quarter.
- 2 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2020 and 4 closed out, a net change of -2 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2020 was Citadel Advisors, an estimated $93.3K added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2020 was Exane Derivatives, an estimated $120K sold.
Based on aggregated 13F filings for Q3 2020.